Feb 18, 2021
Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference
Feb 04, 2021
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
Jan 14, 2021
NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
Jan 06, 2021
Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 29, 2020
FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831
Dec 10, 2020
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
Nov 17, 2020
Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
Nov 09, 2020
Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting
Oct 29, 2020
Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET
Oct 22, 2020
Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results
Oct 09, 2020
Trading in Alkermes Ordinary Shares Halted Today
Oct 07, 2020
Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831
Sep 18, 2020
Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress
Sep 14, 2020
Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience
Sep 09, 2020
Alkermes to Take Part in Cantor Virtual Global Healthcare Conference
Aug 21, 2020
Virtual FDA Advisory Committee Meeting to Review New Drug Application for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020
Aug 19, 2020
Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors
Aug 17, 2020
American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia
Jul 29, 2020
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
Jul 27, 2020
New Harris Poll Survey Offers Insights into Potential of Telepsychiatry During and After the COVID-19 Pandemic